1. Pink Sheet

Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson

 
• By Cathy Kelly

The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.

CMS' Approach To Valuing Drugs Remains To Be Seen • Source: Shutterstock

Medicare’s price negotiation process is unlikely to involve cost effectiveness approaches in any significant way, at least in the near term, Institute for Clinical and Economic Review President Steve Pearson predicted at the ISPOR annual meeting in Boston earlier this month.

Pearson’s comments to an audience made up of cost effectiveness experts and students were meant to tamp down expectations that the Inflation Reduction Act, which established the Medicare price negotiation program, would move the US toward the kind

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.